These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12887656)

  • 21. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology.
    Walker DG; Lue LF; Tang TM; Adler CH; Caviness JN; Sabbagh MN; Serrano GE; Sue LI; Beach TG
    Neurobiol Aging; 2017 Jun; 54():175-186. PubMed ID: 28390825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.
    Cummings BJ; Pike CJ; Shankle R; Cotman CW
    Neurobiol Aging; 1996; 17(6):921-33. PubMed ID: 9363804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin.
    Maurizi CP
    Med Hypotheses; 2001 Aug; 57(2):156-60. PubMed ID: 11461164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
    Buerger K; Ewers M; Pirttilä T; Zinkowski R; Alafuzoff I; Teipel SJ; DeBernardis J; Kerkman D; McCulloch C; Soininen H; Hampel H
    Brain; 2006 Nov; 129(Pt 11):3035-41. PubMed ID: 17012293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
    García-Jiménez A; Cowburn RF; Ohm TG; Bogdanovic N; Winblad B; Fastbom J
    Brain Res; 1999 Dec; 850(1-2):104-17. PubMed ID: 10629754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of neuritic plaques and tangles to the development and evolution of AD.
    Tiraboschi P; Hansen LA; Thal LJ; Corey-Bloom J
    Neurology; 2004 Jun; 62(11):1984-9. PubMed ID: 15184601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
    Bonkale WL; Cowburn RF; Ohm TG; Bogdanovic N; Fastbom J
    Brain Res; 1999 Feb; 818(2):383-96. PubMed ID: 10082824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
    Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
    Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular Contributions in Alzheimer's Disease-Related Neuropathological Changes: First Autopsy Evidence from a South Asian Aging Population.
    Wijesinghe P; Shankar SK; Yasha TC; Gorrie C; Amaratunga D; Hulathduwa S; Kumara KS; Samarasinghe K; Suh YH; Steinbusch HW; De Silva KR
    J Alzheimers Dis; 2016 Oct; 54(4):1607-1618. PubMed ID: 27589527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melatonin levels in the Alzheimer's disease continuum: a systematic review.
    Nous A; Engelborghs S; Smolders I
    Alzheimers Res Ther; 2021 Feb; 13(1):52. PubMed ID: 33622399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex.
    Lian Q; Ladner CJ; Magnuson D; Lee JM
    Exp Neurol; 2001 Jan; 167(1):158-65. PubMed ID: 11161603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease.
    Wu YH; Zhou JN; Van Heerikhuize J; Jockers R; Swaab DF
    Neurobiol Aging; 2007 Aug; 28(8):1239-47. PubMed ID: 16837102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease.
    Brunner P; Sözer-Topcular N; Jockers R; Ravid R; Angeloni D; Fraschini F; Eckert A; Müller-Spahn F; Savaskan E
    Eur J Histochem; 2006; 50(4):311-6. PubMed ID: 17213040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
    Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
    Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies.
    Sabbagh MN; Reid RT; Hansen LA; Alford M; Thal LJ
    J Neural Transm (Vienna); 2001; 108(10):1149-57. PubMed ID: 11725817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease.
    Glöckner F; Meske V; Ohm TG
    Neuroscience; 2002; 114(4):1103-14. PubMed ID: 12379263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression.
    Begcevic I; Tsolaki M; Brinc D; Brown M; Martinez-Morillo E; Lazarou I; Kozori M; Tagaraki F; Nenopoulou S; Gkioka M; Lazarou E; Lim B; Batruch I; Diamandis EP
    F1000Res; 2018; 7():1012. PubMed ID: 30191060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.